Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 4,276,018 shares, a growth of 251.3% from the June 15th total of 1,217,102 shares. Based on an average trading volume of 6,265,161 shares, the short-interest ratio is presently 0.7 days. Approximately 23.1% of the shares of the stock are short sold.

Calidi Biotherapeutics Price Performance

Shares of NYSEAMERICAN:CLDI opened at $0.14 on Monday. The firm has a market capitalization of $2.72 million, a PE ratio of -0.03 and a beta of 1.30. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.92 and a current ratio of 1.92. Calidi Biotherapeutics has a 52-week low of $0.12 and a 52-week high of $11.46. The firm has a fifty day moving average of $0.17 and a 200 day moving average of $0.50.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter.

Hedge Funds Weigh In On Calidi Biotherapeutics

Large investors have recently modified their holdings of the company. DRW Securities LLC bought a new stake in Calidi Biotherapeutics in the 4th quarter worth approximately $173,000. Geode Capital Management LLC boosted its stake in Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after buying an additional 12,334 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Calidi Biotherapeutics during the fourth quarter valued at approximately $25,000. 12.53% of the stock is owned by hedge funds and other institutional investors.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.